CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background and Aims: We previously demonstrated that cancer‐associated fibroblasts (CAFs) promote tumor growth through recruitment of myeloid‐derived suppressor cells (MDSCs). 5‐lipoxygenase (5‐LO) is highly expressed in myeloid cells and is critical for synthesizing leukotriene B4 (LTB4), which is involved in tumor progression by activating its receptor leukotriene B4 receptor type 2 (BLT2). In this study, we investigated whether and how CAFs regulate MDSC function to enhance cancer stemness, the driving force of the cancer aggressiveness and chemotherapy refractoriness, in highly desmoplastic intrahepatic cholangiocarcinoma (ICC). Approach and Results: RNA‐sequencing analysis revealed enriched metabolic pathways but decreased inflammatory pathways in cancer MDSCs compared with blood MDSCs from patients with ICC. Co‐injection of ICC patient‐derived CAFs promoted cancer stemness in an orthotopic ICC model, which was blunted by MDSC depletion. Conditioned media (CM) from CAF‐educated MDSCs drastically promoted tumorsphere formation efficiency and stemness marker gene expression in ICC cells. CAF‐CM stimulation increased expression and activity of 5‐LO in MDSCs, while 5‐LO inhibitor impaired the stemness‐enhancing capacity of MDSCs in vitro and in vivo. Furthermore, IL‐6 and IL‐33 primarily expressed by CAFs mediated hyperactivated 5‐LO metabolism in MDSCs. We identified the LTB4‐BLT2 axis as the critical downstream metabolite signaling of 5‐LO in promoting cancer stemness, as treatment with LTB4 was elevated in CAF‐educated MDSCs, or blockade of BLT2 (which was preferentially expressed in stem‐like ICC cells) significantly reduced stemness‐enhancing effects of CAF‐educated MDSCs. Finally, BLT2 blockade augmented chemotherapeutic efficacy in ICC patient‐derived xenograft models. Conclusions: Our study reveals a role for CAFs in orchestrating the optimal cancer stemness‐enhancing microenvironment by educating MDSCs, and suggests the 5‐LO/LTB4‐BLT2 axis as promising therapeutic targets for ICC chemoresistance by targeting cancer stemness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411 · cited 2×
“Intrahepatic cholangiocarcinoma (ICC) is a subtype of cholangiocarcinoma, the second- most common liver cancer, and its incidence has been increasing in the past few decades worldwide with higher prevalence in Asia.[1] ICC is commonly asymptomatic with a highly aggressive nature and chemotherapy refractoriness, leadin…”
BackgroundFeig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 2×
“Given that CCL2 and CXCL12 secreted by CAFs were previously shown to primarily mediate immune cell recruitment,[12,13,23] and they failed to upregulate 5- LO expression in MDSCs, we chose to focus on IL- 6 and IL- 33, both of which are known to activate myeloid cells.”
BackgroundSu, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Self-citationYang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Self-citationTargeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring
Shi, Y., Gao, W., Lytle, N. K., Huang, P., Yuan, X., Dann, A. M., Ridinger-Saison, M., DelGiorno, K. E., Antal, C. E., Liang, G., et al. (2019) · Nature · doi:10.1038/s41586-019-1130-6 · Cited by 431
Self-citation
Cited by
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao, Y., Shen, M., Wu, L., Yang, H., Yao, Y., Yang, Q., Du, J., Liu, L., Li, Y., & Bai, Y. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06110-6 · Cited by 431
Zhu, G.-Q., Tang, Z., Huang, R., Qu, W.-F., Fang, Y., Yang, R., Tao, C.-Y., Gao, J., Wu, X.-L., Sun, H.-X., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00529-z · Cited by 336
Self-citationRoles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 257
Metadata
- Authors
- Lin, Y., Cai, Q., Chen, Y., Shi, T., Liu, W., Mao, L., Deng, B., Ying, Z., Gao, Y., Luo, H., Yang, X., Huang, X., Shi, Y., & He, R.
- Venue
- Hepatology
- Published
- 2021-12-05
- Volume
- 75
- Issue
- 1
- Pages
- 28-42
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3191072101
- Cited by
- 177
- References
- 5
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.